Literature DB >> 24623866

Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd. #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24623866      PMCID： PMC3940678          DOI： 10.1310/hpj4902-127

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  32 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

2.  Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

Authors:  Jae Yong Cho; Yong Han Paik; Yoon Soo Chang; Se Joon Lee; Dong-Ki Lee; Si Young Song; Jae Bock Chung; Mi-Suk Park; Jeong-Sik Yu; Dong-Sup Yoon
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

3.  Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.

Authors:  Jae-Lyun Lee; Song Cheol Kim; Ji-Hoon Kim; Sang Soo Lee; Tae-Won Kim; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Myung-Hwan Kim; Jong Hoon Kim; Jin-Hong Park; Sang Hyun Shin; Duck Jong Han
Journal:  Surgery       Date:  2012-06-06       Impact factor: 3.982

4.  Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

Authors:  Andrew H Ko; Anne M Espinoza; Kimberly A Jones; Alan P Venook; Emily K Bergsland; Robin K Kelley; Elizabeth Dito; Anna Ong; Cherry S Hanover; Fergus V Coakley; Margaret A Tempero
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

5.  Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.

Authors:  Dieter Koeberle; Piercarlo Saletti; Markus Borner; Daniela Gerber; Daniel Dietrich; Clemens B Caspar; Walter Mingrone; Kurt Beretta; Florian Strasser; Thomas Ruhstaller; Oreste Mora; Richard Herrmann
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

6.  Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.

Authors:  Jürg Bernhard; Daniel Dietrich; Werner Scheithauer; Daniela Gerber; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard C Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Richard Herrmann
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Authors:  Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

9.  Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.

Authors:  S Boeck; T Hoehler; G Seipelt; R Mahlberg; A Wein; A Hochhaus; H-P Boeck; B Schmid; E Kettner; M Stauch; F Lordick; Y Ko; M Geissler; K Schoppmeyer; G Kojouharoff; A Golf; S Neugebauer; V Heinemann
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

10.  A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.

Authors:  Hong Suk Song; Young Rok Do; Heung Moon Chang; Min Hee Ryu; Kyung Hee Lee; Yeul Hong Kim; Dae Sik Hong; Jae Yong Cho; Kyoung Eun Lee; Si Young Kim
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-03       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.